ARS Pharmaceuticals, Inc. (SPRY) SEC Filings & Earnings Calls

Dependence on neffy adoption rate for profitability; if adoption slows, cash burn may extend beyond 2027.

“Path to cash flow breakeven by end of 2027 depends on continued revenue growth and cost discipline.”

CSU clinical program is early-stage; Phase 2b data not expected until Q1 2027, with no guarantee of success.

“Interim data from Phase 2b trial in CSU expected in Q1 2027; no FDA-approved on-demand treatment currently exists.”

Regulatory compliance risk

“On September 9, 2025 and January 23, 2026, we received untitled letters from the HHS regarding our television advertisements.” · word for word

Liquidity risk

“Our net loss for the six months ended June 30, 2026 was $123.0 million. As of June 30, 2026, we had an accumulated deficit of $417.6 million.” · word for word

Debt covenant risk

“The Credit Agreement also contains a minimum liquidity covenant that requires us to maintain at all times at least $25.0 million of unrestricted cash and cash equivalents.” · word for word

Loss of key R&D leadership (CMO) may impact clinical development pipeline.

“CMO Sarina Tanimoto terminated without cause; director Richard Lowenthal resigned.”

Abrupt CEO termination may indicate internal disagreements or performance issues.

“CEO terminated without cause, effective immediately, with no stated reason.”

FDA enforcement on promotional claims

“On September 9, 2025 and January 23, 2026, we received untitled letters from the Department of Health & Human Services regarding our television (“TV”) advertisements. The letters raised concerns from the FDA that our advertisements made false or misleading claims...” · word for word

Most-Favored-Nation pricing policy

“If implemented, a “Most-Favored-Nation” pricing policy that is determined to apply to us and neffy based on a reference to the lowest ex-U.S. list price for our intranasal epinephrine product could significantly reduce the U.S. list price for neffy and likewise reduce our annual market opportunity for neffy in the United States.” · word for word

Continued losses and negative cash flows

“Our net loss for the three months ended March 31, 2026 was $60.6 million. As of March 31, 2026, we had an accumulated deficit of $355.2 million. We expect to continue to incur significant losses for the foreseeable future.” · word for word

Credit agreement restrictive covenants

“The Credit Agreement also contains a minimum liquidity covenant that requires us to maintain at all times at least $25.0 million of unrestricted cash and cash equivalents. These covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our shareholders.” · word for word

High SG&A spend relative to revenue; net loss significant

“SG&A expenses $72.2M vs total revenue $22.7M; net loss $60.6M.”

Dependence on payor access for neffy commercial success

“CVS Caremark proposal in final stages; gross-to-net retention target ~50%.”

Single product dependency

“neffy is the only approved product; revenue is concentrated on this product.”

Commercial execution risk

“Early launch dynamics have been encouraging, but still early in neffy's commercial lifecycle.”

Regulatory and clinical risk

“Phase 2b trial for CSU is underway; results are uncertain.”

Dependence on neffy commercial success

“We are highly dependent on the successful commercialization of neffy. To the extent neffy and EURneffy are not commercially successful, our business, financial condition and results of operations would be materially adversely affected” · word for word

Competition from existing injectable products

“Competitive products may reduce or eliminate the commercial opportunity for neffy or our current and future intranasal epinephrine technology product candidates.” · word for word

Third-party manufacturing reliance

“We rely completely on third parties to manufacture and warehouse both our domestic and international supply of neffy and our current and future intranasal epinephrine technology product candidates.” · word for word

High SG&A spend relative to revenue; net loss significant.

“SG&A expenses $230.1M vs revenue $84.3M in FY2025.”

Cash burn and capital needs

“Our net loss was $130.0 million for the nine months ended September 30, 2025. As of September 30, 2025, we had an accumulated deficit of $253.3 million.” · word for word

Debt covenant restrictions

“The Credit Agreement also contains a minimum liquidity covenant that requires us to maintain at all times at least $25.0 million of unrestricted cash and cash equivalents.” · word for word

Regulatory and pricing pressure

“If implemented, a 'Most-Favored-Nation' pricing policy that is determined to apply to us and neffy based on a reference to the lowest ex-U.S. list price for our intranasal epinephrine product could significantly reduce the U.S. list price for neffy and likewise reduce our annual market opportunity for neffy in the United States.” · word for word

High SG&A spend relative to revenue; net loss significant

“SG&A $74.8M vs revenue $32.5M; net loss $51.2M.”

Commercial execution risk; competition from epinephrine autoinjectors

“DTC investment heavy; gross-to-net retention ≥50% implies pricing pressure.”